Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Clin Immunol. 2018 Mar 21;192:6–13. doi: 10.1016/j.clim.2018.03.010

Table 2.

Demographics by dose.

	Low Dose (500mcg)	High Dose (1000mcg)	p-value
	n=14	n=16	p-value
Median Age (yrs)	54	57	0.80
Range	42–83	41–82
Breast	n=13	n=14
T Stage < T2	61.5%	71.4%	0.69
High Grade	38.5%	35.7%	0.98
Node Positive	69.2%	42.9%	0.25
Hormone Receptor+	69.2%	64.3%	0.99
HER2+	0.0%	35.7%	0.04
Ovarian	n=1	n=2